Perspective Therapeutics, Inc.

NYSEAM:CATX Stock Report

Market Cap: US$343.3m

Perspective Therapeutics Management

Management criteria checks 4/4

Perspective Therapeutics' CEO is Thijs Spoor, appointed in Feb 2023, has a tenure of 3.42 years. total yearly compensation is $2.40M, comprised of 28.3% salary and 71.7% bonuses, including company stock and options. directly owns 0.077% of the company’s shares, worth $263.91K. The average tenure of the management team and the board of directors is 2.9 years and 3.4 years respectively.

Key information

Thijs Spoor

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage28.28%
CEO tenure3.4yrs
CEO ownership0.08%
Management average tenure2.9yrs
Board average tenure3.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Thijs Spoor's remuneration changed compared to Perspective Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$112m

Dec 31 2025US$2mUS$680k

-US$104m

Sep 30 2025n/an/a

-US$106m

Jun 30 2025n/an/a

-US$95m

Mar 31 2025n/an/a

-US$85m

Dec 31 2024US$5mUS$630k

-US$78m

Sep 30 2024n/an/a

-US$58m

Jun 30 2024n/an/a

-US$52m

Mar 31 2024n/an/a

-US$50m

Dec 31 2023US$1mUS$506k

-US$37m

Compensation vs Market: Thijs's total compensation ($USD2.40M) is about average for companies of similar size in the US market ($USD2.41M).

Compensation vs Earnings: Thijs's compensation has been consistent with company performance over the past year.

CEO

Thijs Spoor (54 yo)

3.4yrs
Tenure
US$2,404,692
Compensation

Mr. Johan M. Spoor, also known as Thijs, is Chief Executive Officer and Director at Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) since February 05, 2023. He founded AzurRx BioPharma, Inc...

Leadership Team

NamePositionTenureCompensationOwnership
Johan Spoor
CEO & Director3.4yrsUS$2.40m0.077%
$ 263.9k
Joel Sendek
CFO & Principal Financial Officerless than a yearUS$2.33mno data
Markus Puhlmann
Chief Medical Officer3.4yrsUS$1.07m0.12%
$ 414.0k
Michael Schultz
Co-Founder & Senior Scientific Advisorno datano datano data
Shane Cobb
Executive Vice President of Operations2.9yrsno datano data
Jonathan Hunt
Chief Accounting Officer1.9yrsUS$1.50m0.052%
$ 180.0k
Paul Lyne
Chief Science Officerno datano datano data
Annie Cheng
Vice President of Investor Relationsno datano datano data
Chris Nenno
General Counsel & Corporate Secretaryno datano datano data
Andrew Bright
Executive Vice President of Brachytherapy3.3yrsno datano data
Amos Hedt
Chief Business Strategy Officerno datano datano data
David Hauser
Senior Vice President of Clinical Operationsno datano datano data
2.9yrs
Average Tenure
59yo
Average Age

Experienced Management: CATX's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Johan Spoor
CEO & Director3.4yrsUS$2.40m0.077%
$ 263.9k
Robert Williamson
Independent Director3.4yrsUS$174.40k0.10%
$ 357.7k
Frank Morich
Independent Director3.4yrsUS$174.40kno data
Heidi Henson
Independent Director3.1yrsUS$174.40k0.023%
$ 78.2k
Lori Holmes-Woods
Chairperson of the Board8.1yrsUS$189.40k0.17%
$ 566.7k
Maya Martinez-Davis
Independent Directorless than a yearUS$227.03kno data
3.4yrs
Average Tenure
60yo
Average Age

Experienced Board: CATX's board of directors are considered experienced (3.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/12 06:40
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Perspective Therapeutics, Inc. is covered by 22 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Alec StranahanBofA Global Research
Yuan ZhiB. Riley Securities, Inc.